# A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Source: https://onco.cc/trials/nct05732103/  
OnCo record `nct05732103` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CTX-712 in acute myeloid leukaemia and myelodysplastic syndromes / neoplasms, run by Chordia Therapeutics, Inc., now recruiting.

## Summary

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes is a phase 1/2 interventional study registered as NCT05732103 by Chordia Therapeutics, Inc., with 225 participants planned, started 2023-04-25 and due to reach its primary completion in 2028-06. Interventions recorded: CTX-712.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05732103
- Phase: 1/2
- Setting: Phase 1/2 Multicenter, Open-Label Study of CTX-712 in Patients With Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
- Sponsor: Chordia Therapeutics, Inc.
- Enrolled: 225

## Sources

- ClinicalTrials.gov NCT05732103: https://clinicaltrials.gov/study/NCT05732103

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)

---
JSON: https://onco.cc/api/v1/entities/nct05732103.json